-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Toripalimab is a specific human-derived IgG4K monoclonal antibody against human PD-1 that has a different domain
The CHOICE-01 study evaluated the efficacy and safety
465 patients with advanced NSCLC who did not carry the EGFR/ALK mutation were randomly divided into two groups and received 4 to 6 courses of chemotherapy with Toripalimab (240 mg, n=309) or placebo (1 beat/3 weeks) plus chemotherapy, followed by Toripalimab or placebo with standard of care maintenance
At the time of the final PFS analysis, PFS was significantly longer in the Toripalimab group than in the placebo group (median PFS: 8.
The incidence of grade 3 and above adverse reactions was similar
Together, the findings show that Toripalimab combined chemotherapy significantly improves PFS and OS in patients with untreated advanced NSCLC with controlled safety
Original Source:
Zhijie Wang, et al.